Objective:
To evaluate the potential of melatonin as an adjunctive therapy for systemic lupus erythematosus (SLE) and lupus nephritis, highlighting its significance in managing these conditions.
Approach:
- Melatonin supplementation reduced serum malondialdehyde levels and enhanced antioxidant activity in SLE patients.
- Patients with SLE exhibited lower serum melatonin levels compared to healthy controls, with an inverse correlation to disease activity in females.
- Melatonin showed immunomodulatory effects by influencing T helper cell development and reducing inflammatory cytokine synthesis.
- In animal models, melatonin administration reduced renal damage and improved kidney structure in lupus nephritis.
- Genetic studies identified the MTNR1B rs10830963 polymorphism associated with increased SLE prevalence.
- Variability in melatonin levels may be influenced by circadian timing, disease activity stages, and methodological differences.
- Further research is needed to determine optimal dosing regimens, long-term effects, and the necessity of larger sample sizes.
Key Findings:
Interpretation:
Melatonin has potential as a therapeutic agent in SLE and lupus nephritis, with significant effects on oxidative stress and inflammation, suggesting important clinical implications.
Limitations:
Conclusion:
Melatonin administration may significantly reduce renal damage in SLE by modulating specific proteins associated with fibrosis, apoptosis, oxidative stress, and inflammation, underscoring the need for further research.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
